Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that the company has received favorable coverage decisions for Prolaris® from three new commercial health plans including one of the top five national providers of health insurance.
“We are exceptionally pleased to see continued expansion in coverage for Prolaris which will provide greater access for patients,” said Nicole Lambert, president of Myriad International, Oncology and Women’s Health. “Approximately 60 percent of men with prostate cancer now have access to prognostic testing and we look forward to the day when every man who is facing difficult treatment decisions has access to testing through their health plan.”
The first new coverage policy which can be viewed here became effective June 8, 2020, the second new coverage policy becomes effective on June 15, 2020 and the third new coverage policy which can be viewed here becomes effective on July 31, 2020. In combination, these health plans cover approximately 26 million commercial lives bringing total commercial coverage for Prolaris up to 55 million lives.
Source: GlobeNewswire
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
